State of the art in AIT: The patients’ perspective

Background: On the occasion of the 110(th) anniversary of allergen-specific immunotherapy (AIT), the question arises of “how do patients feel about AIT?”

.

Materials and methods: Informed by questions and feedback provided to MeinAllergiePortal, an online survey with a target of 130 responses was devised and offered for completion by readers.

All visitors of MeinAllergiePortal categories addressing inhalant allergies were invited to participate in the survey.

Participants were grouped and analyzed by their AIT completion status.

The survey was ended once target was met.

Results: 121 of 132 participants were familiar with AIT.

1) A majority of patients who completed AIT would choose the therapy again; 2) Physicians do not seem to discuss AIT with all patients with significant symptoms; 3) Adverse reactions appear to be a major reason why patients terminate AIT prematurely; 4) Lack of time, or early response, as often supposed, does not seem to be a major factor leading to discontinuation of AIT.

Conclusion: Patients’ experience and understanding of symptoms (both related to allergic disease, or expected AIT-related adverse events) appear to be key factors related to AIT engagement and adherence.

Given the importance of adherence for AIT efficacy, improved education and support strategies may assist patients achieve their treatment goals.